These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 2141513)

  • 21. Androgen and taxol cause cell type-specific alterations of centrosome and DNA organization in androgen-responsive LNCaP and androgen-independent DU145 prostate cancer cells.
    Schatten H; Ripple M; Balczon R; Weindruch R; Chakrabarti A; Taylor M; Hueser CN
    J Cell Biochem; 2000 Jan; 76(3):463-77. PubMed ID: 10649443
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prooxidant-antioxidant shift induced by androgen treatment of human prostate carcinoma cells.
    Ripple MO; Henry WF; Rago RP; Wilding G
    J Natl Cancer Inst; 1997 Jan; 89(1):40-8. PubMed ID: 8978405
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The effects of basic fibroblast growth factor and suramin on cell motility and growth of rat prostate cancer cells.
    Pienta KJ; Isaacs WB; Vindivich D; Coffey DS
    J Urol; 1991 Jan; 145(1):199-202. PubMed ID: 1984091
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prostate cancer cells generated during intermittent androgen ablation acquire a growth advantage and exhibit changes in epidermal growth factor receptor expression.
    Hobisch A; Fiechtl M; Sandahl-Sorensen B; Godoy-Tundidor S; Artner-Dworzak E; Ramoner R; Bartsch G; Culig Z
    Prostate; 2004 Jun; 59(4):401-8. PubMed ID: 15065088
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Androgen receptor activation in prostatic tumor cell lines by insulin-like growth factor-I, keratinocyte growth factor, and epidermal growth factor.
    Culig Z; Hobisch A; Cronauer MV; Radmayr C; Trapman J; Hittmair A; Bartsch G; Klocker H
    Cancer Res; 1994 Oct; 54(20):5474-8. PubMed ID: 7522959
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cytostatic effects of suramin on prostate cancer cells cultured from primary tumors.
    Peehl DM; Wong ST; Stamey TA
    J Urol; 1991 Mar; 145(3):624-30. PubMed ID: 1705296
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Suramin inhibits the growth of non-small-cell lung cancer cells that express the epidermal growth factor receptor.
    Fujiuchi S; Ohsaki Y; Kikuchi K
    Oncology; 1997; 54(2):134-40. PubMed ID: 9075785
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Regulation of growth and epidermal growth factor receptor levels of LNCaP prostate tumor cells by different steroids.
    Schuurmans AL; Bolt J; Voorhorst MM; Blankenstein RA; Mulder E
    Int J Cancer; 1988 Dec; 42(6):917-22. PubMed ID: 3263955
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of suramin on growth of androgen-responsive mouse tumor (Shionogi carcinoma 115) and its autonomous subline (Chiba subline 2).
    Furuya Y; Sato N; Watabe Y; Shimazaki J
    Endocrinol Jpn; 1990 Dec; 37(6):933-42. PubMed ID: 1966284
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The effects of coumarin and suramin on the growth of malignant renal and prostatic cell lines.
    Myers RB; Parker M; Grizzle WE
    J Cancer Res Clin Oncol; 1994; 120 Suppl():S11-3. PubMed ID: 8132694
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effect of suramin on the mitogenic response of the human prostate carcinoma cell line PC-3.
    Ewing MW; Liu SC; Gnarra JR; Walther MM; Meyers CE; Linehan WM
    Cancer; 1993 Feb; 71(3 Suppl):1151-8. PubMed ID: 8428338
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [The enhancement of the chemotherapeutic effects on human prostate cancer cell--the combination with the growth factor interaction inhibitor (suramin)].
    Suzuki Y; Miwa Y; Akino H; Fujita T; Saikawa S; Kanimoto Y; Okada K
    Hinyokika Kiyo; 1993 Dec; 39(12):1215-20. PubMed ID: 8285172
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effects of new 17alpha-hydroxylase/C(17,20)-lyase inhibitors on LNCaP prostate cancer cell growth in vitro and in vivo.
    Grigoryev DN; Long BJ; Nnane IP; Njar VC; Liu Y; Brodie AM
    Br J Cancer; 1999 Oct; 81(4):622-30. PubMed ID: 10574247
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Anti-tumour effects and pharmacokinetic profile of 17-(5'-isoxazolyl)androsta-4,16-dien-3-one (L-39) in mice: an inhibitor of androgen synthesis.
    Nnane IP; Long BJ; Ling YZ; Grigoryev DN; Brodie AM
    Br J Cancer; 2000 Jul; 83(1):74-82. PubMed ID: 10883671
    [TBL] [Abstract][Full Text] [Related]  

  • 35. 1alpha,25-dihydroxyvitamin D3 inhibits prostate cancer cell growth by androgen-dependent and androgen-independent mechanisms.
    Zhao XY; Peehl DM; Navone NM; Feldman D
    Endocrinology; 2000 Jul; 141(7):2548-56. PubMed ID: 10875257
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Differential effects of growth factor antagonists on neoplastic and normal prostatic cells.
    Morton RA; Isaacs JT; Isaacs WB
    Prostate; 1990; 17(4):327-36. PubMed ID: 2251224
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Androgen and epidermal growth factor down-regulate cyclin-dependent kinase inhibitor p27Kip1 and costimulate proliferation of MDA PCa 2a and MDA PCa 2b prostate cancer cells.
    Ye D; Mendelsohn J; Fan Z
    Clin Cancer Res; 1999 Aug; 5(8):2171-7. PubMed ID: 10473102
    [TBL] [Abstract][Full Text] [Related]  

  • 38. 1alpha,25-dihydroxyvitamin D3 actions in LNCaP human prostate cancer cells are androgen-dependent.
    Zhao XY; Ly LH; Peehl DM; Feldman D
    Endocrinology; 1997 Aug; 138(8):3290-8. PubMed ID: 9231780
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effects of trapidil and suramin on growth factor-induced calcium response and tyrosine phosphorylation in human glioma cells.
    Bando K; Kannuki S; Rokutan K; Shouno M; Matsumoto K
    Neurol Med Chir (Tokyo); 1995 Sep; 35(9):631-8. PubMed ID: 7566395
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Androgens stimulate fatty acid synthase in the human prostate cancer cell line LNCaP.
    Swinnen JV; Esquenet M; Goossens K; Heyns W; Verhoeven G
    Cancer Res; 1997 Mar; 57(6):1086-90. PubMed ID: 9067276
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.